menu
    • menu
    [{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"HUNGARY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Sumitomo","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"HUNGARY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Sumitomo","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Sumitomo"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gedeon Richter \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Gedeon Richter \/ AbbVie Inc"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gedeon Richter \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Gedeon Richter \/ AbbVie Inc"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"HUNGARY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gedeon Richter \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Hikma Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Gedeon Richter

    Menu

    Gedeon Richter

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie, Gedeon Richter Partner on Neuropsychiatric Drug Discovery

                            Details : Companies will discover and develop novel targets for the treatment of neuropsychiatric conditions. AbbVie will have worldwide commercialization rights except for traditional markets of Richter.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $25.0 million

                            October 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Sumitomo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO® for Treatment of Endometriosis

                            Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

                            Product Name : Ryeqo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 15, 2023

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Sumitomo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

                            Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

                            Product Name : Ryeqo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 11, 2023

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

                            Details : The collaboration is based on results of preclinical research carried by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years, including globally launched products such as caripraz...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 03, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed

                            Gedeon Richter

                            Hungary arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Richter and Hikma Sign Exclusive Commercialisation and License Agreement for Denosumab in the US, a Proposed B...

                            Details : According to the agreement, Richter is responsible for the development of the denosumab, Products (to conduct both Phase 1 and Phase 3 global clinical studies) and will supply finished commercial Products for the US market.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 12, 2021

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth